In conclusion, our results indicate that there is a significant correlation between TLG3.0 and PD-L1 expression levels, suggesting a potential role for 18F-FDG PET/CT to characterize the tumor microenvironment and select CRC patients' candidate to checkpoint inhibitors. The gene discussed is CD274; the disease is neoplasm.